"As Congress nears a January deadline to pass a continuing resolution and avert a government shutdown, critical health programs hang in the balance. The now-expired Affordable Care Act subsidies and proposed cuts to the Ryan White HIV/AIDS program could undermine access to lifesaving services and medications, including Lenacapavir, a breakthrough drug offering new hope in the fight against HIV. Nearly 40 million people worldwide, and more than one million people in the United States,"
"The antiretroviral drug was first approved in 2022 for treating people living with HIV who were highly resistant to other treatments. Subsequent clinical trials demonstrated it was also highly effective (99.9%) in preventing HIV infection, and, in June, the Food and Drug Administration approved its use as a pre-exposure prophylaxis, or PrEP. Unlike other PrEP options, which require oral pills that can be difficult to take consistently, Lenacapavir offers protection through just two injections a year."
Congress faces a January deadline to pass a continuing resolution to avert a government shutdown that could jeopardize health programs. The expiration of Affordable Care Act subsidies and proposed cuts to the Ryan White HIV/AIDS program could undermine access to services and medications, including Lenacapavir. Nearly 40 million people worldwide and over one million in the United States live with HIV, with more than 30,000 Americans newly infected each year. Lenacapavir, approved in 2022 and authorized as PrEP in June, showed 99.9% effectiveness and provides protection with two injections per year. Federal agencies, working with Gilead Sciences and partners, are prioritizing funding and distribution. Gaps in affordability, access, and logistics could squander progress and increase long-term costs.
Read at Advocate.com
Unable to calculate read time
Collection
[
|
...
]